Allergy Therapeutics plc (LON:AGY)‘s stock had its “buy” rating reaffirmed by research analysts at Numis Securities Ltd in a research report issued on Monday. They presently have a GBX 37 ($0.48) price objective on the stock. Numis Securities Ltd’s price objective indicates a potential upside of 89.74% from the stock’s previous close.

A number of other research firms have also issued reports on AGY. Panmure Gordon reissued a “buy” rating and issued a GBX 53 ($0.69) target price on shares of Allergy Therapeutics plc in a report on Thursday, July 14th. Stifel Nicolaus reissued a “buy” rating and issued a GBX 72 ($0.94) target price on shares of Allergy Therapeutics plc in a report on Friday, July 8th.

Allergy Therapeutics plc (LON:AGY) opened at 21.70 on Monday. The firm’s market capitalization is GBX 127.85 million. Allergy Therapeutics plc has a 1-year low of GBX 17.25 and a 1-year high of GBX 34.82. The company has a 50-day moving average price of GBX 18.82 and a 200 day moving average price of GBX 22.15.

In other Allergy Therapeutics plc news, insider Nicolas Wykeman purchased 150,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 27th. The shares were purchased at an average cost of GBX 18 ($0.23) per share, for a total transaction of £27,000 ($35,243.44). Also, insider Peter Jensen purchased 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 29th. The stock was acquired at an average price of GBX 19 ($0.25) per share, for a total transaction of £5,700 ($7,440.28).

Allergy Therapeutics plc Company Profile

Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.

Receive News & Stock Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related stocks with our FREE daily email newsletter.